Mesoblast
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2001-01-01
- Employees
- 73
- Market Cap
- $733.9M
- Website
- http://www.angioblast.com
- Introduction
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 200...
PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT00683722
- Locations
- 🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸Upstate Pharmaceutical Research, Greenville, South Carolina, United States
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)
- Conditions
- Interventions
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 192
- Registration Number
- NCT00562497
- Locations
- 🇺🇸
University of Chicago Hospitals, Chicago, Illinois, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Oncology Hematology Association, Pittsburgh, Pennsylvania, United States
Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT00543374
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Womens Hospital, Boston, Massachusetts, United States
Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT00482092
- Locations
- 🇺🇸
University of Maryland, Baltimore, Baltimore, Maryland, United States
🇺🇸Chevy Chase Clinical Research, Chevy Chase, Maryland, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)
- Conditions
- Interventions
- First Posted Date
- 2006-08-21
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT00366145
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Maryland/Greenbaum, Baltimore, Maryland, United States
🇺🇸Baylor University, Dallas, Texas, United States
Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2006-02-20
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00294112
- Locations
- 🇺🇸
Osiris Clinical Site, Richmond, Virginia, United States
Safety and Efficacy of Prochymal® for the Salvage of Treatment-Refractory Acute GVHD Patients
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT00284986
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00136903
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸St. Francis Hospital, Indianapolis, Indiana, United States
🇺🇸New York Medical College, Valhalla, New York, United States
Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction
- First Posted Date
- 2005-06-15
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00114452
- Locations
- 🇺🇸
Jewish Hospital, Louisville, Kentucky, United States
🇺🇸Washington Adventist, Takoma Park, Maryland, United States
🇺🇸Columbia Presbyterian Hospital, New York, New York, United States